A 2008 panorama on osteoporosis and inflammatory bowel disease

Minerva Medica

Volumn 99, Issue 1, 2008, Pages 65-71

  Sapone, N ^a   Pellicano, R ^a   Simondi, D ^a   Sguazzini, C ^a   Reggiani, S ^a   Terzi, E ^a   Rizzetto, M ^a   Astegiano, M ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Glucocorticoids; Inflammatory bowel diseases; Osteoporosis, risk factors

Indexed keywords

ACEBUTOLOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; GLUCOCORTICOID; INTERLEUKIN 11; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

BONE DENSITOMETRY; BONE DENSITY; CROHN DISEASE; ENTERITIS; HEREDITY; HORMONE SUBSTITUTION; HUMAN; OSTEOCLAST; OSTEOPOROSIS; PATHOGENESIS; REVIEW; RISK FACTOR; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; HYPOGONADISM; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MALABSORPTION SYNDROMES; OSTEOPOROSIS;

EID: 42049113381     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Alexeeva L, Burkardt P, Christiansen C, Cooper C, Delmas P, Johnell O et al. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. WHO Technical Report Series 843, 1994, Geneva, Switzerland, p. 1-129.
2. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000;108:153-64.
3. Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V et al. Peak bone mass. Osteoporosis Int 2000;11:985-1009.
4. Papaioannou A, Ferko NC, Adachi JD. All patients with inflammatory bowel disease should have bone density assessment. Inflamm Bowel Dis 2001;7:158-62.
5. Vestergaard P, Krough K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000;46:176-81.
6. Bernstein CN, Blanchard JF, Leslie W, Waida A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000;133:795-9.
7. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5.
8. Jahmsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathyroid Hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002;37:192-9.
9. Szulc P, Meunier PJ. Is vitamin K deficiency a risk factor for osteoporosis in Crohn's disease? Lancet 2001;357:1995-6.
10. Hessov I, Mosekilde L, Melsen F, Fasth S, Hultèn L, Lund B et al. Osteopenia with normal vitamin D metabolites after small bowel resection for Crohn's disease. Scand J Gastroenterol 1983;19:691-6.
11. Munger RG, Cerhan JR, Chiu BC. Prospective study of dietary protein intake and risk of hip fracture in post-menopausal women. Am J Clin Nutr 1999;24:289-95.
12. Haddad JG Jr, Hahn TJ. Natural and synthetic source of circulating 25-hydroxyvitamin D in man. Nature 1973;244:515-6.
13. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-42.
14. Vogelsang H, Schoft R, Tillinger W, Farenci P, Gangl A. 25-hydroxyvitamin D absorption in patients with Crohn's desease and pancreatic insufficiency. Wien Klin Wochenschr 1997;109:678-82.
15. Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997;32:1247-55.
16. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Churc HA et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28:410-5.
17. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. March 7-29, 2000. Highlights of the conference. South Med J 2001;94:569-73.
18. Bernstein CN, Leslie WD, Tabak SP. Bone density in a population-based cohort of premenopausal adult women with early onset of inflammatory bowel disease. Am J Gastroenterol 2003;98:1094-100.
19. Vleggaar FP, van Buuren HR, Wolfhagen FHJ, Schalm SW, Pols HAP. Prevention and treatment of osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 999;11:337-49.
20. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348-60.
21. Van Staa TP, Cooper C, LeufkensHG, Bishop N. Children and the risk of fractures cause by oral corticosteroids. J Bone Miner Res 2003;18:913-8.
22. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
23. Bernstein N, Lesile WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol 2003;15:857-64.
24. Gilbert L, He X, Farmer P, Boden S, Kozlowski M, Rubin J et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000;141:3956-64.
25. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000;275:4858-64.
26. Kuroucochi K, Kambe F, Yasukawa K, Izumi R, Ishiguro N, Iwata H et al. TNF-alpfa increases expression of IL-6 and ICAM-1 genes through activation of NF-kappa B in osteoblasts-like ROS1 7/2.8 cells. J Bone Miner Res 1998;13:1290-9.
27. Radeff JM, Nagy Z, Stern PH. Involvement of PKC-beta in PTH, TNF-alpha, and IL-1 beta effects on IL-6 promoter in osteoblastic cells and on PTH-stimulated bone resorption. Exp Cell Res 2001;268:179-88.
28. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodelling. Emerging insights into the pathophisiology of osteoporosis. N Engl J Med 1995;332:305-11.
29. Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res 2002;17:1563-9.
30. Holloway WR, Colier FM, Aitken CJ, Myers DE, Hodge JM, Malakelis M et al. Leptin inhibits osteoclasts generation. J Bone Miner Res 2002;17:200-9.
31. Jahnsen J, Falch JA, MowinckelP, Aadland E. Body composition in patients with inflammatory bowel disease: a population-based study. Am J Gastroenterol 2003;98:1556-62.
32. Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low bone mass density in Crohn's disease. Inflamm Bowel Dis 2002;8:87-92.
33. Weber AM, Ziegler C, Belinson JL, Mitchinson AR, Widrich T, Fazio V. Gynaecologic history of women with inflammatory bowel disease. Obste Gynecol 1995;86:843-7.
34. Szathmari M, Vasarhelyi B, Trezsl A, Tulassay T, Tulassay Z. Association of dehydroepiandrosterone sulphate and testosterone deficiency with bone turnover in men with inflammatory bowel disease. Int J Colorectal Dis 2002;17:63-6.
35. Robinson RJ, Iqbal SJ, Al Azzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. Aliment Pharmacol Ther 1998;12:21-5.
36. Straub RH, Vogl D, Gross V, Lang B, Scholmerich J, Andus T. association of humoral markers of inflammation and dehydroepiandrosterone sulphate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am J Gastroenterol 1998;83:2197-202.
37. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease and ulcerative colitis: a nationwide follow-up study of 16416 patients in Denmark. Am J Epidemiol 2002;156:1-10.
38. Bernstein CN, Blanchard JF, Rawsthorne P, Waida A. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999;149:916-24.
39. Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ. Long term fracture risk in patients with Crohn's disease: a population based study in Olmsted Country, Minnesota. Gastroenterology 2002;123:468-75.
40. Hahn TJ. Metabolic bone disease. In: Kelly WN, Harris ED, Ruddy S et al., editors. Textbook of rheumathology. 4th ed. Philadelphia: WB Saybinders; 1993. p. 1593-627.
41. Von Tirpitz C, Reinshagen M. Management of osteoporosis in aptients with gastrointestinal disease. Eur J Gastroenterol Hepatol 2003;15:869-76.
42. American College of Rheumathology Task force on osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791-801.
43. Ellerington MC, HillArd TC, Whitcroft DI, Marsh MS, Lees B, Banks LM et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996;59:6-11.
44. Cheanut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fracture study. PROOF Study Group. Am J Med 2000;109:267-76.
45. Downs RW Jr, Bell NH, Ettnger MP, Walsh BW, Favus MJ, Mako B et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000;85:1783-8.
46. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.